SciELO - Scientific Electronic Library Online

 
vol.89 issue5Cardiopulmonary Exercise Test in Heart Transplant RecipientsUnprotected Left Main Percutaneous Coronary Intervention: One and 3-Year Evolution. Event Prediction author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista argentina de cardiología

On-line version ISSN 1850-3748

Abstract

SEOANE, LEONARDO A. et al. Venoarterial Extracorporeal Membrane Oxygenation for Refractory Cardiogenic Shock and Cardiac Arrest: An Initial 7-Year Experience in an Adult Cardiology Center. Rev. argent. cardiol. [online]. 2021, vol.89, n.5, pp.422-428.  Epub Oct 05, 2021. ISSN 1850-3748.  http://dx.doi.org/10.7775/rac.es.v89.i5.20436.

Background:

Venoarterial extra corporeal membrane oxygenation (VA-ECMO) is a rescue intervention used in patients with cardiogenic shock (CS) or cardiac arrest (CA) refractory to conventional medical therapies.

Objective:

The aim of the present study is to describe the characteristics and summarize our 7-year experience in patients with CS or CA supported with VA-ECMO.

Methods:

We conducted a single-center retrospective study analyzing consecutive adult patients requiring VA-ECMO due to refractory CS or CA at ICBA, Instituto Cardiovascular between January 2014 and December 2020.

Results:

A total age 54 patients were included (54 ± 12 years), 36.5% presented ischemic cardiomyopathy and 23.1% significant valvular heart disease. The indications for VA-ECMO implantation were post-cardiotomy (43.4%), refractory CS (28.3%) and primary graft dysfunction (20.8%). Cardiopulmonary resuscitation before VA-ECMO occurred in 18.5% of the cases. Peripheral cannulation was performed in 81.5% of the cases, 83.3% had INTERMACS profile 1 and 87% were on intraaortic balloon pump. Duration of ventricular assistance on VA- ECMO was 5.5 days (IQR 2.8-10). Survival rate on ECMO VA was 63% (37% as a bridge to cardiac transplantation and 26% as a bridge to recovery) and survival to discharge was 42.6%. The most common complications were hemorrhage (61.1%), infections (51.9%), and thromboembolic complications (46.3%).

Conclusion:

In our center, VA-ECMO as a treatment for refractory CS or CA showed acceptable survival during ventricular support and on hospital discharge. It is an effective life support treatment to rescue critically ill patients when conventional therapies fail, is apparently useful and can be implemented in a country with limited resources and access to complex ventricular assist devices.

Keywords : Extracorporeal Membrane Oxygenation; Cardiogenic shock; Postcardiotomy shock; Ventricular assist devices.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )